6F26
Crystal structure of human Casein Kinase I delta in complex with compound 31b
6F26 の概要
| エントリーDOI | 10.2210/pdb6f26/pdb |
| 分子名称 | Casein kinase I isoform delta, SULFATE ION, (9~{S},10~{S},11~{R})-~{N}-[4-[3-(4-fluorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]pyridin-2-yl]-4-(4-methoxyphenyl)-10,11-bis(oxidanyl)-1,7-diazatricyclo[7.3.0.0^{3,7}]dodeca-3,5-diene-6-carboxamide, ... (4 entities in total) |
| 機能のキーワード | kinase, inhibitor, complex, ck1, transferase |
| 由来する生物種 | Homo sapiens (Human) |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 75828.32 |
| 構造登録者 | |
| 主引用文献 | Luxenburger, A.,Schmidt, D.,Ianes, C.,Pichlo, C.,Kruger, M.,von Drathen, T.,Brunstein, E.,Gainsford, G.J.,Baumann, U.,Knippschild, U.,Peifer, C. Design, Synthesis and Biological Evaluation of Isoxazole-Based CK1 Inhibitors Modified with Chiral Pyrrolidine Scaffolds. Molecules, 24:-, 2019 Cited by PubMed Abstract: In this study, we report on the modification of a 3,4-diaryl-isoxazole-based CK1 inhibitor with chiral pyrrolidine scaffolds to develop potent and selective CK1 inhibitors. The pharmacophore of the lead structure was extended towards the ribose pocket of the adenosine triphosphate (ATP) binding site driven by structure-based drug design. For an upscale compatible multigram synthesis of the functionalized pyrrolidine scaffolds, we used a chiral pool synthetic route starting from methionine. Biological evaluation of key compounds in kinase and cellular assays revealed significant effects of the scaffolds towards activity and selectivity, however, the absolute configuration of the chiral moieties only exhibited a limited effect on inhibitory activity. X-ray crystallographic analysis of ligand-CK1δ complexes confirmed the expected binding mode of the 3,4-diaryl-isoxazole inhibitors. Surprisingly, the original compounds underwent spontaneous Pictet-Spengler cyclization with traces of formaldehyde during the co-crystallization process to form highly potent new ligands. Our data suggests chiral "ribose-like" pyrrolidine scaffolds have interesting potential for modifications of pharmacologically active compounds. PubMed: 30832206DOI: 10.3390/molecules24050873 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.83 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






